Dr. Zhang brings decades of experience in life sciences to lead Himalaya.  He is a venture partner at Yuanming Capital and an angel investor, focused on biomedical investment.  He was president and cofounder of Tairan Biopharma and founder/CEO of Novomed Technologies.  Dr. Zhang co-invented the first gene chip-based diagnostic for subtyping breast cancers when he was at Arcturus Applied Genomics in San Diego, California.  Dr. Zhang also spent a decade at Hoffmann-La Roche in Nutley, New Jersey, where he held many roles, including Senior Scientist and Principal Investigator, and he was involved in the development of Xenical, the world’s first oral obesity drug, and the discovery of Dorzagliatin, for type II diabetes.  He was a leader overseeing the Roche-Takeda project and a team member of the first interdepartmental bioinformatics project for Roche US, leading and building an animal disease model center and implemented a database system to support Roche globally.   Dr. Zhang was at PricewaterhouseCoopers (PwC) in New York as a Senior Business Consultant, where he led and provided business analysis and information system consultation to the pharmaceutical industry in the tri-state area.  He received his B.S. in Biology from Nanjing University, did brain research at the Graduate School of the Chinese Academy of Sciences before earning a highly competitive scholarship to study abroad, and he received his Ph.D. in Neuroscience from the UCLA School of Medicine.  Dr. Zhang is an author on dozens of peer reviewed publications in top scientific journals